Your browser doesn't support javascript.
loading
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.
Hirata, Koichi; Takeshima, Takao; Imai, Noboru; Igarashi, Hisaka; Shiosakai, Masako; Inage, Masanobu; Sakurai, Fumi; Ning, Xiaoping; Nakai, Masami; Koga, Nobuyuki.
Afiliação
  • Hirata K; Headache Center, Department of Neurology, Dokkyo Medical University, Tochigi, Japan.
  • Takeshima T; Headache Center, Department of Neurology, Headache Center Tominaga Hospital, Osaka, Japan.
  • Imai N; Department of Neurology, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
  • Igarashi H; Headache Care Unit, Department of Internal Medicine, Fujitsu Clinic, Kanagawa, Japan.
  • Shiosakai M; Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co Ltd, Tokyo, Japan.
  • Inage M; Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co Ltd, Tokyo, Japan.
  • Sakurai F; Clinical Development, Headquarters of Clinical Development Otsuka Pharmaceutical Co Ltd, Tokyo, Japan.
  • Ning X; Speciality Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA, USA.
  • Nakai M; Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan.
  • Koga N; Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan.
Expert Opin Drug Saf ; 22(6): 447-454, 2023.
Article em En | MEDLINE | ID: mdl-36578197
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article